Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg

Inclusion Criteria: * Age: Between 19 to 45 years of age, inclusive (age based on the date to give the informed consent) * Ideal body weight (Broca index): between 50 to 90 kg, inclusive, and within ±20 % of Ideal Body Weight, \[(Height in cm-100)×0.9\] * Subjects who are appropriate to participate in this study judged from clinical laboratory and physical examinations taken within 4weeks prior to the start of study * Subjects who are able to abstain from caffeine or caffeine-containing products (e.g., coffee, cola, tea, chocolate), grapefruit and grapefruit containing products, alcohol and smoking within 7 days before dosing and during the hospitalization * Subjects who give their informed consent voluntarily to participate in the study Exclusion Criteria: * History of allergies including drug allergy, except untreated, asymptomatic, seasonal allergies at the time of dosing * Use any medication not considered acceptable by the clinical investigator during the last 10 days period before the start day of the study * Use of any inducer or inhibitors of metabolizing enzymes during the last 28 days before the start day of the study. * History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease * History of a significant surgical resection of gastrointestinal tract except appendectomy * Abnormal clinical laboratory findings, especially for AST or ALT \> 1.25 fold, total bilirubin \> 1.5 fold of upper normal level * Pregnant or lactating woman or woman of childbearing potential without medically acceptable birth control during the study * Evidence of alcohol abuse (defined as regular alcohol intake that exceeds 24 oz \[675 ml\] of beer, 12 oz \[340 ml\] of wine or 160 ml of soju or 3 oz \[85 ml\] hard liquor per day \[e.g., brandy, whiskey, gin\]) or drug abuse * Heavy smokers (\> 10 cigarettes per day), or can't quit smoking during hospitalization * Participation in clinical trials of any drug within 3 months prior to the start of study * Donation of 200ml of whole blood within 4 weeks or 400ml within 12 weeks prior to the start of study * Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or HIV antibody * Judged to be inappropriate for the study by the investigator